Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 6:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 830 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Safety and Pharmacokinetics in Healthy Volunteer Subjects Clear all
Terminated Phase 1 Interventional Accepts healthy volunteers

SAD and MAD Study of FTX-101 in Healthy Male Subjects

NCT06617546
View directory record Official record
Conditions
Healthy Volunteers
Interventions
FTX-101, Placebo
Drug
Lead sponsor
Find Therapeutics
Industry
Eligibility
18 Years to 59 Years · Male only
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Oct 14, 2026, 6:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of Flufirvitide-3 Nasal Spray in Healthy Subjects

NCT01313962
View directory record Official record
Conditions
Influenza
Interventions
Flufirvitide-3 0.05 mg single dose, Flufirvitide-3, 0.1 mg single dose, Flufirvitide-3, 0.2 mg single dose, Flufirvitide-3, 0.4 mg single dose, Placebo
Drug · Other
Lead sponsor
Autoimmune Technologies, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 16, 2012 · Synced Oct 14, 2026, 6:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate HT-6184 in Healthy Subjects

NCT05447546
View directory record Official record
Conditions
Normal Healthy Subjects
Interventions
HT-6184, HT-6184 Placebo
Drug
Lead sponsor
Halia Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 28, 2023 · Synced Oct 14, 2026, 6:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP1617 in Healthy Adult Non-Asian and Japanese Subjects Including Assessment of a Food Effect

NCT04077879
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ASP1617, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Oct 14, 2026, 6:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

First in Human Study to Assess Safety of VIS649 in Healthy Subjects

NCT03719443
View directory record Official record
Conditions
Immunoglobulin A Nephropathy, IgAN - IgA Nephropathy, IgA Nephropathy
Interventions
VIS649, Placebo
Biological
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 14, 2026, 6:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetics of VNRX-5133 in the Epithelial Lining Fluid of Healthy Adult Subjects

NCT03870490
View directory record Official record
Conditions
Healthy Subjects
Interventions
VNRX-5133 + cefepime
Drug
Lead sponsor
Venatorx Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated May 6, 2019 · Synced Oct 14, 2026, 6:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

AZD6280 Multiple Ascending Dose Study

NCT00681317
View directory record Official record
Conditions
Healthy Volunteer
Interventions
AZD6280
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 9, 2010 · Synced Oct 14, 2026, 6:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessment of Pharmacokinetics and Safety of M923 Administered Via Auto-injector or Prefilled Syringe, in Healthy Subjects

NCT02675023
View directory record Official record
Conditions
Healthy
Interventions
M923
Biological
Lead sponsor
Momenta Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
603 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2019 · Synced Oct 14, 2026, 6:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess Safety, Tolerability, and Pharmacokinetics of Oral Doses for AC430 in Healthy Subjects

NCT01287858
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
AC430
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 45 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 2, 2015 · Synced Oct 14, 2026, 6:02 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate HLA-G Targeted Exosome (SOB100) in Healthy Subjects

NCT07219940
View directory record Official record
Conditions
Healthy Subjects, Exosome, Targeted Therapy
Interventions
SOB100
Drug
Lead sponsor
Shine-On Biomedical Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 14, 2026, 6:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single and Multiple Dose of Rodatristat Ethyl in Healthy Adult Subjects to Evaluate the Effect of Food and Safety

NCT05684640
View directory record Official record
Conditions
Healthy
Interventions
Rodatristat Ethyl, Placebo
Drug
Lead sponsor
Altavant Sciences GmbH
Industry
Eligibility
18 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 27, 2023 · Synced Oct 14, 2026, 6:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Hutrukin to Analyze Safety and PK in Healthy Volunteers

NCT05098080
View directory record Official record
Conditions
Pharmacokinetics
Interventions
Hutrukin, Placebo
Biological
Lead sponsor
XBiotech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 23, 2024 · Synced Oct 14, 2026, 6:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study in Healthy Volunteers to Assess Safety and Blood Levels of AZD9742 After Multiple Doses Over 14 Days

NCT01064388
View directory record Official record
Conditions
Healthy
Interventions
AZD9742, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
23 Years to 45 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 6, 2012 · Synced Oct 14, 2026, 6:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

DDI Study of ASC41 in HV and the PK, Safety and Tolerability in Subjects With NAFLD.

NCT04845646
View directory record Official record
Conditions
Healthy, NAFLD
Interventions
ASC41, Itraconazole, Phenytoin
Drug
Lead sponsor
Gannex Pharma Co., Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 27, 2024 · Synced Oct 14, 2026, 6:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GNS-3545 in Healthy Participants

NCT07225296
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
GNS-3545, GNS-3545 Placebo
Drug
Lead sponsor
Genosco Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 14, 2026, 6:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Two-Part, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DS-7309 in Healthy Volunteers and Subjects With Type 2 Diabetes Mellitus

NCT01862939
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
DS-7309, placebo
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 45 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated May 27, 2013 · Synced Oct 14, 2026, 6:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of LY3372993 in Healthy Participants and Participants With Alzheimer's Disease (AD)

NCT03720548
View directory record Official record
Conditions
Alzheimer Disease
Interventions
LY3372993, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 85 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
11
States / cities
Long Beach, California • Daytona Beach, Florida • DeLand, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2019 · Synced Oct 14, 2026, 6:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Second Study to Determine the Effect of GSK256073A on HVTs

NCT00551694
View directory record Official record
Conditions
Healthy Subjects, Dyslipidaemias
Interventions
GSK256073A tablets
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 4, 2012 · Synced Oct 14, 2026, 6:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Determine the Effect of 500 mg Oral Dose of KD025 in Healthy Male and Post-menopausal Female Subjects

NCT05918614
View directory record Official record
Conditions
Immune System Disorder (Healthy Volunteer)
Interventions
Belumosudil mesylate, Placebo
Drug
Lead sponsor
Kadmon, a Sanofi Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 26, 2023 · Synced Oct 14, 2026, 6:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First Time in Human Study to Assess GSK2336805 in Healthy Volunteers and Single Doses in Chronically Infected Hepatitis C Patients.

NCT01277692
View directory record Official record
Conditions
Hepatitis C
Interventions
GSK2336805 10mg, GSK2336805 30mg, GSK2236805 100mg, GSK2236805 200mg, GSK2236805 10mg, GSK2236805 dose to be determined up to 100mg, GSK2236805 5mg, GSK2236805 30mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
3
States / cities
Chula Vista, California • Lenexa, Kansas • Willingboro, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 28, 2017 · Synced Oct 14, 2026, 6:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single Ascending Dose Study of CD101 IV in Healthy Subjects

NCT02516904
View directory record Official record
Conditions
Healthy
Interventions
CD101 IV, Placebo
Drug
Lead sponsor
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated May 22, 2024 · Synced Oct 14, 2026, 6:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Multiple Dose Study Of BIIB118 (PF-05251749) In Healthy Volunteers

NCT02691702
View directory record Official record
Conditions
Healthy Adult Subjects, Healthy Elderly Subjects
Interventions
BIIB118, Melatonin
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 85 Years
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
2
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Oct 14, 2026, 6:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of Single Ascending Doses of PUL-042 Inhalation Solution in Healthy Subjects

NCT02124278
View directory record Official record
Conditions
Healthy
Interventions
PUL-042 Inhalation Solution
Drug
Lead sponsor
Pulmotect, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 29, 2015 · Synced Oct 14, 2026, 6:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics and Safety of Fevipiprant in Patients With Renal Impairment Compared to Matched Healthy Subjects

NCT03087942
View directory record Official record
Conditions
Renal Insufficiency
Interventions
QAW039, QAW39A, QAW39A2107
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Dec 11, 2020 · Synced Oct 14, 2026, 6:02 AM EDT